3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received only a conditional recommendation for use and, thus, to date no drugs are strongly recommended for IPF. The aim of this study was to assess the effectiveness and safety of the currently approved drugs for IPF and N-acetylcysteine (NAC), the most debated drug in the last update of guidelines for IPF treatment.

          Related collections

          Author and article information

          Journal
          Pulm Pharmacol Ther
          Pulmonary pharmacology & therapeutics
          Elsevier BV
          1522-9629
          1094-5539
          Oct 2016
          : 40
          Affiliations
          [1 ] University of Rome Tor Vergata, Department of Systems Medicine, Unit of Respiratory Clinical Pharmacology, Rome, Italy; University of Rome Tor Vergata, Department of Systems Medicine, Chair of Respiratory Medicine, Rome, Italy.
          [2 ] University of Rome Tor Vergata, Department of Systems Medicine, Unit of Respiratory Clinical Pharmacology, Rome, Italy. Electronic address: luigino.calzetta@uniroma2.it.
          [3 ] University of Rome Tor Vergata, Department of Systems Medicine, Chair of Respiratory Medicine, Rome, Italy.
          [4 ] Second University of Naples, Department of Experimental Medicine, Unit of Pharmacology, Naples, Italy.
          Article
          S1094-5539(16)30061-X
          10.1016/j.pupt.2016.07.009
          27481628
          757c0d62-b0f5-4592-9000-619f8b31c48f
          History

          IPF,Therapy,Meta-analysis
          IPF, Therapy, Meta-analysis

          Comments

          Comment on this article